

Peptide Array, Dengue Virus Type 3, Sleman/1978, E Protein

Catalog No. NR-511

This reagent is the tangible property of the U.S. Government.

For research use only. Not for human use.

Contributor:

NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH

Product Description:

The 68-peptide array spans the E protein of Dengue virus type 3, Sleman/1978 (GenPept: AAT69740).¹ Peptides are 12- to 20-mers, with 10 or 11 amino acid overlaps. Please see Table 1 for length and sequence of individual peptides.

Material Provided:

Peptides are provided lyophilized at 1 mg per vial.

Packaging/Storage:

Lyophilized peptides should be placed in a closed, dry environment with dessicants and stored at -20°C or colder immediately upon arrival. A frost-free freezer should be avoided, since changes in moisture and temperature may affect peptide stability.

Solubility:

Solubility may vary based on the amino acid content of the individual peptide (see Table 2).

Reconstitution:

Lyophilized peptides should be warmed to room temperature for 1 hour prior to reconstitution. They should be dissolved at the highest possible concentration, and then diluted with water or buffer to the working concentration. Buffer should be added only after the peptide is completely in solution because salts may cause aggregation.

The most common dissolution process is 1 mg of peptide in 1 mL of sterile, distilled water. Peptides that are not soluble in water can almost always be dissolved in DMSO. Once a peptide is in solution, the DMSO can be slowly diluted with aqueous medium. Care must be taken to ensure that the peptide does not begin to precipitate out of solution. For cellbased assays, 0.5% DMSO is usually well-tolerated.

Sonication and/or the addition of small amounts of dilute (10%) aqueous acetic acid for basic peptides, aqueous ammonia for acidic peptides or acetonitrile may also help dissolution (see Table 2). These solvents may not be appropriate for certain applications, including cell-based assays.

Storage of Reconstituted Peptides:

The shelf life of peptides in solution is very limited, especially for sequences containing cysteine, methionine, tryptophan, asparagine, glutamine, and N-terminal glutamic acid. In general, peptides may be aliquoted and stored in solution for a few days at -20°C or colder. For long-term storage, peptides should be re-lyophilized and stored at -20°C or colder. If long-term storage in solution is unavoidable, peptide solutions should be buffered to pH 5–6, aliquoted and stored at -20°C or colder. Freeze-thaw cycles should be avoided.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through the NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH: Peptide Array, Dengue Virus Type 3, Sleman/1978, E Protein, NR-511."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. <u>Biosafety in</u> <u>Microbiological and Biomedical Laboratories</u>. 5th ed. Washington, DC: U.S. Government Printing Office, 2007; see www.cdc.gov/od/ohs/biosfty/bmbl5/bmbl5/bc.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for humans use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at <u>www.beiresources.org</u>.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC[®] nor the U.S. Government make any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC[®] nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC[®] and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC[®], their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

800-359-7370 Fax: 703-365-2898 E-mail: <u>contact@beiresources.org</u>



Use Restrictions:

This material is distributed for internal research, noncommercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if license is required. U.S. Government contractors may need a license before first commercial sale. This material may be subject to third party patent rights.

References:

 Blaney, J. E. Jr., et al. "Genetically Modified, Live Attenuated Dengue Virus Type 3 Vaccine Candidates." <u>Am. J. Trop. Med. Hyg.</u> 71 (2004): 811–821. PubMed: 15642976. GenPept: AAT69740.

 $\mathsf{ATCC}^{\circledast}$ is a trademark of the American Type Culture Collection.





Table 1				
Peptide	Length	Sequence		
1	18	MRCVGVGNRDFVEGLSGA		
2	17	RDFVEGLSGATWVDVVL		
3	16	SGATWVDVVLEHGGCV		
4	17	DVVLEHGGCVTTMAKNK		
5	17	GCVTTMAKNKPTLDIEL		
6	18	KNKPTLDIELQKTEATQL		
7	18	ELQKTEATQLATLRKLCI		
8	18	TQLATLRKLCIEGKITNV		
9	15	LCIEGKITNVTTDSR		
10	18	KITNVTTDSRCPTQGEAI		
11	19	SRCPTQGEAILPEEQDQNH		
12	17	ILPEEQDQNHVCKHTYV		
13	15	DQNHVCKHTYVDRGW		
14	17	CKHTYVDRGWGNGCGLF		
15	16	RGWGNGCGLFGKGSLV		
16	18	CGLFGKGSLVTCAKFQCL		
17	18	LVTCAKFQCLESIEGKVV		
18	17	CLESIEGKVVQHENLKY		
19	17	KVVQHENLKYTVIITVH		
20	17	LKYTVIITVHTGDQHQV		
21	17	TVHTGDQHQVGNETQGV		
22	18	HQVGNETQGVTAEITPQA		
23	17	GVTAEITPQASTVEAIL		
24	18	PQASTVEAILPEYGTLGL		
25	18	ILPEYGTLGLECSPRTGL		
26	18	GLECSPRTGLDFNEMILL		
27	18	GLDFNEMILLTMKNKAWM		
28	17	LLTMKNKAWMVHRQWFF		
29	16	AWMVHRQWFFDLPLPW		
30	15	RQWFFDLPLPWTSGA		
31	17	DLPLPWTSGATTETPTW		
32	17	SGATTETPTWNKKELLV		
33	18	PTWNKKELLVTFKNAHAK		
34	17	LVTFKNAHAKKQEVVVL		

	Table 1 (continued)					
Peptide	Length	Sequence				
35	18	HAKKQEVVVLGSQEGAMH				
36	16	VLGSQEGAMHTALTGA				
37	18	GAMHTALTGATEIQTSGG				
38	18	GATEIQTSGGTSIFAGHL				
39	18	GGTSIFAGHLKCRLKMDK				
40	18	HLKCRLKMDKLELKGMSY				
41	18	DKLELKGMSYAMCLNAFV				
42	15	SYAMCLNAFVLKKEV				
43	18	LNAFVLKKEVSETQHGTI				
44	17	EVSETQHGTILIKVEYK				
45	18	GTILIKVEYKGEDAPCKI				
46	20	YKGEDAPCKIPFSTEDGQGK				
47	17	PFSTEDGQGKAHNGRLI				
48	17	GQGKAHNGRLITANPVV				
49	17	GRLITANPVVTKKEEPV				
50	18	PVVTKKEEPVNIEAEPPF				
51	17	PVNIEAEPPFGESNIVI				
52	18	PPFGESNIVIGIGDKALK				
53	16	VIGIGDKALKINWYKK				
54	18	KALKINWYKKGSSIGKMF				
55	18	KKGSSIGKMFEATARGAR				
56	15	MFEATARGARRMAIL				
57	17	ARGARRMAILGDTAWDF				
58	17	AILGDTAWDFGSVGGVL				
59	18	WDFGSVGGVLNSLGKMVH				
60	17	VLNSLGKMVHQIFGSAY				
61	17	MVHQIFGSAYTALFSGV				
62	18	SAYTALFSGVSWIMKIGI				
63	17	GVSWIMKIGIGVLLTWI				
64	15	IGIGVLLTWIGLNSK				
65	16	LLTWIGLNSKNTSMSF				
66	18	LNSKNTSMSFSCIVIGII				
67	18	SFSCIVIGIITLYLGAVV				
68	12	IITLYLGAVVQA				



		Table 2	
Peptide	Solubility	Solvent	Reconstitution pH, if required
1	1 mg/mL	Water	
2	1 mg/mL	30% acetonitrile in water	pH 8.0
3	1 mg/mL	30% acetonitrile in water	
4	1 mg/mL	Water	
5	1 mg/mL	Water	
6	1 mg/mL	Water	
7	1 mg/mL	Water	
8	1 mg/mL	Water	
9	1 mg/mL	Water	
10	1 mg/mL	Water	
11	1 mg/mL	Water	
12	1 mg/mL	Water	
13	1 mg/mL	Water	
14	1 mg/mL	Water	
15	1 mg/mL	Water	
16	1 mg/mL	Water	
17	1 mg/mL	50% acetonitrile in water	
18	1 mg/mL	Water	
19	1 mg/mL	Water	
20	1 mg/mL	Water	
21	1 mg/mL	Water	
22	1 mg/mL	Water	
23	1 mg/mL	Water	
24	1 mg/mL	Water	
25	1 mg/mL	Water	
26	1 mg/mL	50% acetonitrile in water	
27	1 mg/mL	30% acetonitrile in water	
28	1 mg/mL	Water	
29	1 mg/mL	50% acetonitrile in water	
30	1 mg/mL	Water	
31	1 mg/mL	Water	
32	1 mg/mL	Water	
33	1 mg/mL	Water	
34	1 mg/mL	Water	
35	1 mg/mL	Water	
36	1 mg/mL	Water	
37	1 mg/mL	70% acetonitrile in water	
38	1 mg/mL	Water	
39	1 mg/mL	Water	
40	1 mg/mL	Water	

Biodefense and Emerging Infections Research Resources Repository P.O. Box 4137 Manassas, VA 20108-4137 USA www.beiresources.org 800-359-7370 Fax: 703-365-2898 E-mail: <u>contact@beiresources.org</u>



		Table 2 (continued)	
Peptide	Solubility	Solvent	Reconstitution pH, if required
41	1 mg/mL	30% acetonitrile in water	pH 8.0
42	1 mg/mL	Water	
43	1 mg/mL	Water	
44	1 mg/mL	Water	
45	1 mg/mL	Water	
46	1 mg/mL	Water	
47	1 mg/mL	Water	
48	1 mg/mL	Water	
49	1 mg/mL	Water	
50	1 mg/mL	Water	
51	1 mg/mL	Water	
52	1 mg/mL	Water	
53	1 mg/mL	Water	
54	1 mg/mL	Water	
55	1 mg/mL	Water	
56	1 ma/mL	Water	
57	1 mg/mL	40% acetonitrile in water	
58	1 ma/mL	Water	pH 8.0
59	1 mg/mL	Water	
60	1 mg/mL	Water	
61	1 mg/mL	70% acetonitrile in water	
62	1 mg/mL	Formic acid	
63	1 mg/mL	Formic acid	
64	1 mg/mL	Water	
65	1 mg/mL	Formic acid	
66	1 mg/mL	70% acetonitrile in water	
67	1 mg/mL	Formic acid	
68	1 mg/mL	Formic acid	